PEPT

25.9501.48%

Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Viking Therapeutics presented new results from its Phase 2 VENTURE obesity trial of injectable VK2735 at ObesityWeek 2026. * Most treated participants improved their obesity classification over 13 weeks, outperforming placebo; none shifted to a higher BMI category. * Participants whose obesity classification improved showed greater reductions in cardiovascular and metabolic risk markers than those whose classification remained unchanged. * The ongoing Phase 3 VANQUISH program evaluates weekly injectable VK2735, with trial completion expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611151205PR_NEWS_USPR_____LA98030) on November 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.